BRIEF-Aeglea BioTherapeutics - Dialogue with FDA results in delay in initiating dosing in U.S. pediatric patients By: Reuters: Company News May 23, 2017 at 08:12 AM EDT * Aeglea BioTherapeutics provides AEB1102 program and corporate update Read More >> Related Stocks: Aeglea Biothera